Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 19/20 | 0.81 |
| ▸ | ALOX5 | P09917 | 7/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.81 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.72 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quiflapon SCHEMBL30505315 | 0.89 | ALOX5AP (1.00) | ALOX5APALOX5CYP3A4CYP2C9CYP2D6 | |
| Quiflapon SCHEMBL29370879 | 0.89 | ALOX5AP (1.00) | ALOX5APALOX5CYP3A4CYP2C9CYP2D6 | |
| Quiflapon SCHEMBL502947 | 0.89 | ALOX5AP (1.00) | ALOX5APALOX5CYP3A4CYP2C9CYP2D6 | |
| Quiflapon SCHEMBL29372303 | 0.89 | ALOX5AP (1.00) | ALOX5APALOX5CYP3A4CYP2C9CYP2D6 | |
| Quiflapon SCHEMBL9306842 | 0.89 | ALOX5AP (0.98) | ALOX5APALOX5CYP3A4CYP2C9CYP2D6 | |
| Quiflapon SCHEMBL9306864 | 0.89 | ALOX5AP (0.98) | ALOX5APALOX5CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL2109531 | 0.89 | ALOX5AP (0.85) | ALOX5APALOX5CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL2108478 | 0.87 | ALOX5AP (1.00) | ALOX5APALOX5CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL3775490 | 0.86 | ALOX5AP (0.81) | ALOX5APALOX5CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL2108907 | 0.86 | PTGS1 (0.87) | ALOX5APALOX5CYP3A4CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150320697-A1 | Methods For Bone Treatment By Modulating An Arachidonic Acid Metabolic or Signaling Pathway | ACCELALOX, INC. | 2015-11-12 | — | — | US | claimed |
| EP-1947942-B1 | METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | ACCELALOX INC (US) | 2015-07-29 | — | — | EP | claimed |
| US-8980851-B2 | Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway | ACCELALOX, INC. (US) | 2015-03-17 | — | — | US | claimed |
| WO-2014031586-A2 | METHODS FOR TREATING CARDIOVASCULAR DISEASES | TALLIKUT PHARMACEUTICALS, INC. (US) | 2014-02-27 | — | — | WO | claimed |
| US-20110124717-A1 | Methods for Bone Treatment by Modulating an Arachidonic Acid Metabolic or Signaling Pathway | ACCELALOX, INC. (US) | 2011-05-26 | — | — | US | claimed |
| US-7829535-B2 | for promoting osteogenesis to accelerate or enhance bone fracture healing, treat bone defects, and enhance bone formation are disclosed. The methods modulate an arachidonic acid metabolic or signaling pathway in general, and, in particular, utilize 5-lipoxygenase inhibitors. | ACCELALOX, INC. (US) | 2010-11-09 | — | — | US | claimed |
| US-20080280826-A1 | for promoting osteogenesis to accelerate or enhance bone fracture healing, treat bone defects, and enhance bone formation are disclosed. The methods modulate an arachidonic acid metabolic or signaling pathway in general, and, in particular, utilize 5-lipoxygenase inhibitors. | ACCELALOX, INC. (US) | 2008-11-13 | — | — | US | claimed |
| WO-1993010115-A1 | AMORPHOUS (QUINOLIN-2-YLMETHOXY) INDOLES AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1993-05-27 | — | — | WO | claimed |
| US-20150320697-A1 | Methods For Bone Treatment By Modulating An Arachidonic Acid Metabolic or Signaling Pathway | ACCELALOX, INC. | 2015-11-12 | — | — | US | disclosed |
| EP-1947942-B1 | METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | ACCELALOX INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-8980851-B2 | Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway | ACCELALOX, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| WO-2014031586-A2 | METHODS FOR TREATING CARDIOVASCULAR DISEASES | TALLIKUT PHARMACEUTICALS, INC. (US) | 2014-02-27 | — | — | WO | disclosed |
| US-20110269807-A1 | NOVEL TREATMENT FOR AGE RELATED MACULAR DEGENERATION AND OCULAR ISCHEMIC DISEASE ASSOCIATED WITH COMPLEMENT ACTIVATION BY TARGETING 5-LIPOXYGENASE | ALLERGAN, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110124717-A1 | Methods for Bone Treatment by Modulating an Arachidonic Acid Metabolic or Signaling Pathway | ACCELALOX, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20040198800-A1 | Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents | INSMED INCORPORATED | 2004-10-07 | — | — | US | disclosed |
| US-6756399-B2 | INHIBITORS OF ENZYMES THAT METABOLIZE ARACHIDONIC ACID; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2004-06-29 | — | — | US | disclosed |
| US-20030082108-A1 | Inhibitors of enzymes that metabolize arachidonic acid; peroxisome proliferator-activated receptors (ppar) | GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY, THE | 2003-05-01 | — | — | US | disclosed |
| US-6071949-A | FOR TREATMENT OF CANCERS DERIVED FROM EPITHELIAL CELLS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-06-06 | — | — | US | disclosed |
| EP-0750496-A1 | USE OF LIPOXYGENASE INHIBITORS AS ANTI-CANCER THERAPEUTIC AND INTERVENTION AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-01-02 | — | — | EP | disclosed |
| WO-1995024894-A2 | USE OF LIPOXYGENASE INHIBITORS AS ANTI-CANCER THERAPEUTIC AND INTERVENTION AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269807-A1 | NOVEL TREATMENT FOR AGE RELATED MACULAR DEGENERATION AND OCULAR ISCHEMIC DISEASE ASSOCIATED WITH COMPLEMENT ACTIVATION BY TARGETING 5-LIPOXYGENASE | ALOX15B, ALOX5, ALOX15 | ALOX5AP 5/4885ALOX5 2/4885CYP3A4 3178/4885 |
| US-20040198800-A1 | Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents | ALOX5, ALOX15, ALOX15B | ALOX5AP 7/4885ALOX5 1/4885CYP3A4 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.